FDA Discloses Safety Reviews Of COX-2s Arcoxia, Prexige and Parecoxib

Merck's Arcoxia is linked to an increase in cardiovascular adverse events across multiple analyses, FDA reviewers state in briefing documents for the upcoming COX-2 inhibitor safety review